NCT04382651 - Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

January 6, 2021

Study Completion Date

April 21, 2021

Conditions

COVID-19 Pneumonia, Impaired Respiratory Function

Interventions

DRUG

MAS825

MAS825 liquid solution for intravenous infusion

OTHER

Placebo

Placebo liquid solution for intravenous infusion

DRUG

Standard of Care (SoC)

SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Trial Locations (21)

11219

Novartis Investigative Site, Brooklyn

19140

Novartis Investigative Site, Philadelphia

20037

Novartis Investigative Site, Washington D.C.

28805

Novartis Investigative Site, Asheville

43214

Novartis Investigative Site, Columbus

70596

Novartis Investigative Site, Lafayette

70809

Novartis Investigative Site, Baton Rouge

71301

Novartis Investigative Site, Alexandria

75149

Novartis Investigative Site, Mesquite

77030

Novartis Investigative Site, Houston

80220

Novartis Investigative Site, Denver

83404

Novartis Investigative Site, Idaho Falls

90404

Novartis Investigative Site, Santa Monica

90503

Novartis Investigative Site, Torrance

91206

Novartis Investigative Site, Glendale

91911

Novartis Investigative Site, Chula Vista

91942

Novartis Investigative Site, La Mesa

92697

Novartis Investigative Site, Irvine

97701

Novartis Investigative Site, Bend

02115

Novartis Investigative Site, Boston

02118

Novartis Investigative Site, Boston